Recurrent C3 glomerulopathy after kidney transplantation
Copyright © 2024 Elsevier Inc. All rights reserved..
The complement system is part of innate immunity and is pivotal in protecting the body against pathogens and maintaining host homeostasis. Activation of the complement system is triggered through multiple pathways, including antibody deposition, a mannan-binding lectin, or activated complement deposition. C3 glomerulopathy (C3G) is a rare glomerular disease driven by complement dysregulation with high post-transplantation recurrence rates. Its treatment is mainly based on immunosuppressive therapies, specifically mycophenolate mofetil and glucocorticoids. Recent years have seen significant progress in understanding complement biology and its role in C3G pathophysiology. New complement-tergeting treatments have been developed and initial trials have shown promising results. However, challenges persist in C3G, with recurrent post-transplantation cases leading to suboptimal outcomes. This review discusses the pathophysiology and management of C3G, with a focus on its recurrence after kidney transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Transplantation reviews (Orlando, Fla.) - 38(2024), 2 vom: 03. Apr., Seite 100839 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Obata, Shota [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C3 |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.trre.2024.100839 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369025296 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369025296 | ||
| 003 | DE-627 | ||
| 005 | 20240405233644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.trre.2024.100839 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM369025296 | ||
| 035 | |a (NLM)38412598 | ||
| 035 | |a (PII)S0955-470X(24)00022-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Obata, Shota |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrent C3 glomerulopathy after kidney transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a The complement system is part of innate immunity and is pivotal in protecting the body against pathogens and maintaining host homeostasis. Activation of the complement system is triggered through multiple pathways, including antibody deposition, a mannan-binding lectin, or activated complement deposition. C3 glomerulopathy (C3G) is a rare glomerular disease driven by complement dysregulation with high post-transplantation recurrence rates. Its treatment is mainly based on immunosuppressive therapies, specifically mycophenolate mofetil and glucocorticoids. Recent years have seen significant progress in understanding complement biology and its role in C3G pathophysiology. New complement-tergeting treatments have been developed and initial trials have shown promising results. However, challenges persist in C3G, with recurrent post-transplantation cases leading to suboptimal outcomes. This review discusses the pathophysiology and management of C3G, with a focus on its recurrence after kidney transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a C3 | |
| 650 | 4 | |a C3 glomerulopathy | |
| 650 | 4 | |a C3aR | |
| 650 | 4 | |a C5 | |
| 650 | 4 | |a C5aR1 | |
| 650 | 4 | |a Complement-mediated glomerulonephritis | |
| 650 | 4 | |a MAC | |
| 650 | 4 | |a Recurrent glomerulonephritis | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a eculizumab | |
| 650 | 7 | |a Complement C3 |2 NLM | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 700 | 1 | |a Vaz de Castro, Pedro A S |e verfasserin |4 aut | |
| 700 | 1 | |a Riella, Leonardo V |e verfasserin |4 aut | |
| 700 | 1 | |a Cravedi, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation reviews (Orlando, Fla.) |d 1992 |g 38(2024), 2 vom: 03. Apr., Seite 100839 |w (DE-627)NLM031132510 |x 1557-9816 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:03 |g month:04 |g pages:100839 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.trre.2024.100839 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 03 |c 04 |h 100839 | ||